CSCs contribute to the anticancer drug resistance by numerous mechanisms, including EMT regulation, enhanced expression of ABC transporters, overexpression of aldehyde dehydrogenase (ALDH) enzyme, slow cycling of microRNAs, regulation of tumor microenvironment, as well as resistance to DNA damage and cell death [15]. The gene discussed is LDHA; the disease is neoplasm.